Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2017 ASCO Annual Meeting /
Phase III results of olaparib for BRCA breast cancer

2nd - 6th Jun 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.06.17
Views: 2028

Dr Mark Robson - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Robson speaks with ecancer at ASCO 2017 about the growth-limiting application of olaparib, a PARP inhibitor, to treat BRCA breast cancer.

He describes how, among 300 women included in the trial, disease progression was slowed by up to 3 months, reducing the chance of disease progression by 42%.

For more, watch Dr Robson speak at the press session in which these results were announced, or read about the findings here.

The data has also been published in The New England Journal of Medicine .

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation